These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 9333106

  • 1. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
    Jorga KM, Sedek G, Fotteler B, Zürcher G, Nielsen T, Aitken JW.
    Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
    [Abstract] [Full Text] [Related]

  • 2. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects.
    Dingemanse J, Jorga K, Zürcher G, Fotteler B, Sedek G, Nielsen T, van Brummelen P.
    Eur J Clin Pharmacol; 1996 Sep; 50(1-2):47-55. PubMed ID: 8739811
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers.
    Jorga KM.
    Neurology; 1998 May; 50(5 Suppl 5):S31-8. PubMed ID: 9591520
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T, Machado R, Rocha JF, Fernandes-Lopes C, Costa R, Torrão L, Loureiro AI, Falcão A, Vaz-da-Silva M, Wright L, Almeida L, Soares-da-Silva P.
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G.
    Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation.
    Jorga K, Fotteler B, Sedek G, Nielsen T, Aitken J.
    J Neurol; 1998 Apr; 245(4):223-30. PubMed ID: 9591224
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
    Davis TL, Roznoski M, Burns RS.
    Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
    Jorga KM, Nicholl DJ.
    Br J Clin Pharmacol; 1999 Sep; 48(3):449-52. PubMed ID: 10510160
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.